circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis-Reference-Cited by-同舟云学术

circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis

Published:2021-03-26 Issue:3 Volume:377 Page:358-367
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Jiang Zhipeng,Hou Zehui,Liu Wei,Yu Zhuomin,Liang Zhiqiang,Chen Shuang

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference29 articles.

1. Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy

2. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

4. MYC regulates the antitumor immune response through CD47 and PD-L1;Casey;Science,2016

5. Advances and challenges in targeting FGFR signalling in cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Roles of CircRNA-miRNA Networks in Cancer Development and Therapeutic Response;Non-coding RNA Research;2024-09

2. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy;International Journal of Nanomedicine;2024-05

3. Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study;International Journal of Molecular Sciences;2024-03-23

4. Circ_0007422 Knockdown Inhibits Tumor Property and Immune Escape of Colorectal Cancer by Decreasing PDL1 Expression in a miR-1256-Dependent Manner;Molecular Biotechnology;2024-01-22

5. Research Progress of miR-485-3p in Digestive System Tumors;Advances in Clinical Medicine;2024